Abstract: Scientists at the Indiana University School of Medicine have uncovered a surprising connection between aging blood mutations and the severity of inflammatory bowel disease. Their research links Clonal Hematopoiesis of Indeterminate Potential (CHIP), a condition where blood stem cells acquire mutations with increased gut inflammation seen in diseases like Crohn’s Disease and Ulcerative Colitis. By analyzing data from the UK Biobank and the All of Us Research Program, researchers found that individuals with CHIP mutations faced significantly higher risks of severe IBD. In laboratory models, these mutated blood cells were shown to intensify inflammation in the colon. Encouragingly, the team discovered that blocking the APE1/Ref-1 inflammation pathway with the drug APX3330 dramatically reduced inflammation and restored colon health. If future clinical trials confirm these findings, targeting CHIP-driven inflammation could open a completely new therapeutic strategy, one that treats the root biological mechanisms of IBD without suppressing the immune system.
Read the full article here: https://medicine.iu.edu/news/2026/03/ibd-blood-mutations-treatment-target
